Q1: 2026-05-06 Earnings Summary EPS of $0.54 beats by $0.00  |  Revenue of $492.32M (1.83% Y/Y) misses by $6.88M Qiagen N.V. ( QGEN ) Discusses Strategic Priorities and Latest Developments for QuantiFERON and Latent Tuberculosis Testing May 7, 2026 9:30 AM EDT Company Participants Domenica Martorana - Associate Director of Global Investor Relations Thierry Bernard - CEO, MD & Member of Management Board Nadia Aelbrecht Nitin Sood - Senior VP & Head of Product Portfolio & Innovation Parampal Deol Conference Call Participants Riccardo Triunfo Presentation Domenica Martorana Associate Director of Global Investor Relations Welcome to our spotlight session. Today, it's all about QuantiFERON. And in the next hour, you will learn more about our strategic priorities and the latest developments. But before we start, let's have a closer look into the legal disclaimer. As with any investor event, this presentation includes a safe harbor statement.…